CytoBioscience expects to become a much stronger company with significantly more access to capital once its transformation from being privately owned to publicly traded is complete. I reported last month that the San Antonio-based biotech had essentially acquired, through merger, a subsidiary of…
News
- CytoBioscience CEO: Going public will speed growth
- A small boutique landed a lucrative lead role on the $8.7 billion Novartis-AveXis deal
Dyal Co., a small M&A boutique, landed a lead role on the the $8.7 billion Novartis-AveXis deal. The firm has roughly 15 employees and is led by ex-Goldman Sachs rainmaker Gordon Dyal. Dyal was the former co-chairman of investment banking at Goldman, where he spent years leading M&A…
- Novartis just handed out a $8.7 billion endorsement for new therapies that are changing how we ...
Novartis isn't the only big pharma/biotech to be interested in gene and cell therapies. In January, Celgene made a $9 billion bet on Juno Therapeutics, a cancer drugmaker that's working on cell therapies. The deal also drummed up excitement for a possible deal for Bluebird Bio, another company…
- Frontier Airlines launching new SA flights to several destinations
“Raleigh-Durham is an especially important area for research and development,” said Maria Zannes, president and CEO of San Antonio-based bioAffinity Technologies. “North Carolina's universities and medical centers most certainly can be important partners for San Antonio's biotech sector.”.
- Collaborate with institute advisers for academic support, says team lead
Maria Rogers, Health and Biosciences Institute advising team lead, has been the team lead adviser for a year at this college, but was a senior ... Students wanting to transfer to Texas A&M University-San Antonio or the University of Texas at San Antonio can speak with a university adviser in…